Ad
Search
Generic filters
Filter by content type
Taxonomy terms

MEBI – Medicamen Biotech Ltd

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Medicamen Biotech Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing pharmaceutical formulations products. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company is primarily focused on oncology therapeutics. The Company is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. The Company’s oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, Nilotinib HCI, Oxaliplatin, Pazopanib, Pomalidomide and Tegafur. The Company has two manufacturing plants at Bhiwadi (Rajasthan) and Haridwar (Uttarakhand). The Company’s wholly owned subsidiary is OPAL Pharmaceuticals Pty Ltd.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses